{"id":6321,"date":"2025-04-08T18:00:08","date_gmt":"2025-04-08T15:00:08","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=6321"},"modified":"2025-04-08T18:00:08","modified_gmt":"2025-04-08T15:00:08","slug":"todays-news-and-trends-in-cardiology-highlighted-by-aha-acc","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/todays-news-and-trends-in-cardiology-highlighted-by-aha-acc\/","title":{"rendered":"Today\u2019s News and Trends in Cardiology highlighted by AHA\/ACC:"},"content":{"rendered":"
Today\u2019s News and Trends in Cardiology highlighted by AHA\/ACC:<\/div>\n
<\/div>\n
1. TAVR Comparable to Open Heart Surgery After 5 Years in Low-Risk Patients<\/span><\/div>\n
Dr. Michael J. Reardon presented data at ACC.25 indicating that transcatheter aortic valve replacement (TAVR) with a supra-annular, self-expanding valve is a safe and effective alternative to surgical aortic valve replacement (SAVR) in low-risk patients over a five-year period.<\/div>\n
2. Semaglutide Shows Benefits for PAD Patients with Diabetes<\/span><\/div>\n
The STRIDE study, unveiled at ACC.25, demonstrated that semaglutide significantly enhances walking distance, alleviates symptoms, and improves quality of life in patients with symptomatic peripheral artery disease (PAD) and type 2 diabetes.<\/div>\n
3. FDA Declines Approval of Etripamil Nasal Spray for Heart Rhythm Disorders<\/span><\/div>\n
Milestone Pharmaceuticals announced that the FDA has withheld approval for etripamil, a nasal spray intended to treat paroxysmal supraventricular tachycardia (PSVT) and atrial fibrillation with rapid ventricular response (AFib RVR), requesting additional information and a new facility inspection.<\/div>\n
4. Oral Semaglutide Reduces Cardiovascular Events in Type 2 Diabetes Patients<\/span><\/div>\n
Findings from the SELECT trial indicate that oral semaglutide lowers the risk of major adverse cardiovascular events in individuals with type 2 diabetes and established cardiovascular disease, offering a needle-free option for patients.<\/div>\n
5. GE HealthCare Introduces Revolution Vibe CT Scanner with AI Capabilities<\/span><\/div>\n
GE HealthCare has launched the Revolution Vibe, a new CT system featuring Unlimited One-Beat Cardiac imaging and advanced AI solutions designed to enhance cardiac imaging efficiency and diagnostic accuracy.<\/div>\n
6. ACC Releases Guidance on Cardiogenic Shock Management<\/span><\/div>\n
The American College of Cardiology has published its first Concise Clinical Guidance document, offering best practices for the evaluation and management of patients experiencing cardiogenic shock.<\/div>\n
7. Abbott\u2019s Volt PFA System Receives CE Mark Approval<\/span><\/div>\n
Abbott has obtained CE Mark approval for its Volt\u2122 Pulsed Field Ablation (PFA) System, enabling the treatment of patients with atrial fibrillation in Europe. The system utilizes high-energy electrical pulses for targeted cardiac tissue ablation. The Volt\u2122 Pulsed Field Ablation (PFA) System differs from existing ablation technologies in several key ways:<\/div>\n
1. Energy Type: Unlike traditional radiofrequency (RF) or cryoablation, which rely on heat or freezing, PFA uses high-energy electrical pulses to create non-thermal ablation. This minimizes the risk of collateral damage to surrounding tissues, such as the esophagus or phrenic nerve.<\/span><\/div>\n
2. Selectivity: PFA is more tissue-selective, primarily affecting cardiac myocytes while sparing other structures. This makes it potentially safer and more precise than RF or cryoablation.<\/span><\/div>\n
3. Speed and Efficiency: PFA procedures are generally faster than RF ablation, as they do not require the prolonged contact time needed for thermal lesion formation.<\/span><\/div>\n
<\/div>\n
In summary, Abbott\u2019s Volt PFA System represents a newer, non-thermal approach to atrial fibrillation ablation with potentially improved safety, efficiency, and precision compared to traditional methods.<\/div>\n","protected":false},"excerpt":{"rendered":"

Today\u2019s News and Trends in Cardiology highlighted by AHA\/ACC: 1. TAVR Comparable to Open Heart Surgery After 5 Years in Low-Risk Patients Dr. Michael J. Reardon presented data at ACC.25 indicating that transcatheter aortic valve replacement (TAVR) with a supra-annular, self-expanding valve is a safe and effective alternative to surgical aortic valve replacement (SAVR) in […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-6321","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/6321","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=6321"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/6321\/revisions"}],"predecessor-version":[{"id":6322,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/6321\/revisions\/6322"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=6321"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=6321"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=6321"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}